

**PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes**  
**300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011**

**Wednesday, January 19, 2022 – 12:00 PM – 1:30 PM**

- Present:** Meghan McNelly, PharmD, Germaine Biksey, Jill Schaeffer, RN,  
Dr. Mahmood Usman, Dr. Kolin Good, Dr. Christopher Hughes, Dr. Venkateswara Davuluri, Dr. Carla Huitt
- Absent:** Debbie Rose (Participant Advisory), Michelle Bennett, RPh, Dr. Keith Brown
- Guests:** William Baker (Pharmacy), Amy Nowacki (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), Rhonda Hredzak (Pharmacy), George Kimbrow, Jr. (PHW Policy Coordinator), Marci Kramer (QI Director), Heather Clarke (Program Director and Behavioral Health Liaison), Jacci Rowe (Director, Compliance), Shirley Stahler.
- Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:04 PM.
- Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:24 PM.
- Next Meeting:** Wednesday, April 13, 2022 – 12:00 PM
- Submitted By:** Shalyn Kline (PHW Pharmacy)

**Committee Chair:** \_\_\_\_\_  
Shalyn Kline, PharmD

**Date:** 4/13/2022

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:04 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	None			Meghan McNelly
B. Announcements	<p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	No action required or taken.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> <li>i. Voting and vote totals</li> <li>ii. Tie breaker</li> <li>iii. Pennsylvania’s Review and Approval Process</li> </ul>	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q4_2021. No objections were made.	Adoption of Q4_2021 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business				
A. Policy Submission Status	There are no outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline/Meghan McNelly

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

<b>New Business</b>				
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.			Meghan McNelly
B. Alzheimer’s Disease	<p>Voting members were asked if there were any objections to the education. Dr. Usman stated that it is not mentioned that the Montreal Cognitive Assessment (MoCA) is being used more instead of the mini mental state screening MMSE.</p> <p>Bill Baker said he would take Dr. Usman’s concerns back to the Drug Information Team (DI) for consideration. Bill asked Dr. Usman if he could give the DI team his contact information so he could supply them with all his concerns. Dr. Usman stated that he could.</p>	Dr. Usman had concerns for the education.	Bill Baker will send concerns to DI team.	Bill Baker/Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
D. Drug Coverage Criteria	<p>There were a number of policy changes made by the state. There were no issues addressed.</p> <p>Shalyn asked the Committee if anyone had issues with any of the supplemental drug list changes. There were no issues addressed.</p> <p>The Committee was asked if they had any issues with the Ambetter policy changes. There were no issues addressed.</p> <p>*Please note the following recusals from participation in voting and discussion:</p> <ul style="list-style-type: none"> <li>• Dr Kolin Good: <ul style="list-style-type: none"> <li>○ CP.PHAR.366 Calquence</li> <li>○ CP.PMN.64 Seroquel XR</li> </ul> </li> </ul>	The policy revisions were Committee approved.		Shalyn Kline

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

<p>E. Complaints and Grievances Review</p>	<p>Meghan stated that there were three determinations upheld and four overturned. The totals are going down.</p> <p>Meghan asked Dr. Hughes and Dr. Davuluri if they think the complaints and grievances are going down because of the prescreening that is being completed. Dr. Hughes said that he believes that has helped.</p> <p>Meghan stated that Shalyn Kline has designed fax forms to send to the providers that address specific criteria to help the provider be clearer in their response for a prior authorization. She also said that Provider Relations is educating the providers.</p> <p>For the year 2021, there was a 13% decrease overall. The Pharmacy is open to suggestions for anything that may help with decreasing the numbers further.</p> <p>There were four recurring Opioids identified.</p>			<p>Meghan McNelly</p>
<p>F. Drug Utilization Review</p>	<p>Shalyn Kline presented the drug utilization review.</p> <p>FWA – There were 46 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. No Participants were identified with three or more practices/hospitals prescribing opioids.</p> <p>Inappropriate prescribing – No Participants were identified potentially using &gt;4gm/day. There were 10 repeat Participants identified to be on an antipsychotic with an inferred dementia diagnosis.</p> <p>Disease management – There were 17 identified long-acting beta-agonist monotherapy. All were reviewed.</p>			<p>Shalyn Kline</p>

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

G. PBM Oversight	<p>In Q4, there were 120 requests audited. (60 approvals, 60 denials).</p> <p>Findings for the denials were six requests had errors in the denial language and two requests the wrong policy was utilized.</p> <p>Coaching was completed with the Envolve clinical reviewers to prevent future occurrences.</p>			Jason Skaria
I. COVID 19 Response	Continuing point-of-sale edits for “refill too soon”.	No action required or taken.		Meghan McNelly
J. Help Wanted	<ul style="list-style-type: none"> <li>Participant member wanted to join the Committee so we can get their input on how we can be better with CHC.</li> </ul>			
K. Open Forum	No concerns or questions brought up.	No action required or taken.		Meghan McNelly
Adjournment	The meeting was adjourned at 12:24 pm	Meeting adjourned		Meghan McNelly

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).